N.L. Tsapaeva, S.F. Zolotuhina, E.V. Mironova, N.V. Tarashkevich, N.I. Egorova
The aim of present study investigate the clinical, instrumental and biochemical markers of the risk of cardiovascular complicated in long-term of initial percutaneous coronary intervention.
keywords: percutaneous coronary intervention, incomplete myocardial revascularization, microvascular disfunction, biochemical markers of cardiovascular complicated, infrared laser treatment, ranolazin treatment

for references: N.L. Tsapaeva, S.F. Zolotuhina, E.V. Mironova N.V. Tarashkevich, N.I. Egorova. Prevention of cardiovascular complications in the long-term period of initial percutaneous coronary intervention. Neotlozhnaya kardiologiya i kardioovaskulyarnye riski [Emergency cardiology and cardiovascular risks], 2019, vol. 3, no. 2, pp. 726–732

1. Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J, 2010, vol. 31, pp. 2501–555.
2. «Stent 4 Life». Targeting PCI at all who will benefit the most. A joint project between EAPCI, Euro-PCR, EUCOMED and the ESC Working Group on Acute Cardiac Care. Eur Interv, 2009, vol. 4, pp. 555–557.
3. Safley D., House J. Marso S. Grantham J.A., Rutherford B.D. Improvement in survival following successful percutaneous coronary intervention of coronary chronic total occlusions: variability by target vessel. JACC Cardiovasc Interv, 2008, vol. 1, no. 3, pp. 295–302.
4. Sambuceti G., Marzilli M., Mari A., Marini C., Schluter M., Testa R., Papini M., Marraccini P., Ciriello G., Marzullo P., L’Abbate A. Coronary microcirculatory vasoconstriction is heterogeneously distributed in acutely ischemic myocardium. Am J Physiol Heart Circ Physiol, 2005, vol. 288, no. 5, pp. 2298–2305.
5. Bokeriya L.A., Stupakov I.N., Samorodskaya I.V. Ozenka effektivnosti metodov revaskulyarizazii miokarda v randomizirovannych issledovaniyach [Evaluation of the effectiveness of myocardial revascularization methods in randomized trials]. Byulleten’ NZSSCh Serdechno-sosudistye zabolevaniya, 2001, no. 5, pp. 16–50. (in Russian).
6. Kaufmann P., Camici P. Myocardial blood flow by PET: technical aspects and clinicalapplications. J Nucl Med, 2005, vol. 46, no. 1, pp. 75–88.
7. Zapaeva N.L. Tarashkevich N.V., Mironova E.V., Chernoglaz P.F., Yurlevich D.I. Mikrozirkulyatornaya disfunkziya u pazientov s nepolnoy revaskulyarizaziey miokarda v otdalennom periode pervichnogo chrezkozhnogo koronarnogo vmeshatel’stva (vozmozhnosti diagnostiki i lecheniya) [Microvascular dysfunction in patients with incomplete myocardial revascularization in the long -term period of primar y percutaneous coronar y inter vention (diagnosis and treatment opportunities)]. Neotlozhnaya kardiologiya i kardiovaskulyarnye riski, 2017, vol. 1, no. 1, pp. 125–130. (in Russian).
8. Zapaeva N.L., Tarashkevich N.V., Mironova E.V., Chernoglaz P.F., Yurlevich D.I. Vozmozhnosti antianginal’noy terapii u pazientov s nepolnoy revaskulyarizaziey miokarda v otdalennom periode pervichnogo chrezkoronarnogo koronarnogo vmeshatel’stva [Antianginal treatment options of patients with incomplete myocardial revascularization in the long-term period after primary percutaneous coronary intervention]. Neotlozhnaya kardiologiya i kardiovaskulyarnye riski, 2018, vol. 2, no. 2, pp. 392–396. (in Russian).
9. Prasad A., Rihal C., Lennon R. Trends in outcomes after percutaneous coronary intervention for chronic totalocclusions: a 25-year experience from the mayo сlinic. J Am Coll Cardiol, 2007, vol. 49, no. 15, pp. 1611–1618.
10. Zapaeva N.L., Chernoglaz P.F., Yurlevich D.I., Mironova E.V., Kolb M.V., Zhuk O.I. Otdalennye rezul’taty endovaskulyarnoy revaskulyarizazii miokarda u pazientov s ostrym koronarnym sindromom [Long-term eff ectiveness of endovascular myocardil revascularization in patients with acute coronary syndrome]. Kardiologiya v Belarusi, 2017, no. 3, pp. 614–618. (in Russian).
11. Zapaeva N.L., Russkich I.I., Chernoglaz P.F, Yurlevich D.I, Mironova E.V, Kolb M.V. Monitoring dvoynoy anitrombozitarnoy terapii posle ekstrennoy revaskulyarizazii miokarda u pazientov s OKS [Monitoring of double antiplatelet therapy after emergency myocardial revascularization in patients with ACS]. I Mezhdunarodnyy kongress kardiologov i terapevtov : sb. nauch. tr., Minsk, 2016, pp. 313–318. (in Russian).
12. Medvedeva E.A., Gelis L.G., Lazareva I.V., Russkich I.I Klinicheskoe znachenie testirovaniya funkzional’noy aktivnosti trombozitov u pazientov s nestabil’noy stenokardiey pri konservativnoy strategii lecheniya [Clinical importance of the testing of the functional activity of trombocytes in patients with unstable angina with the conservative treatment strategy]. Kardiologiya v Belarus, 2017, no. 3, pp. 508–512. (in Russian).
13. Komarov A.L., Panchenko E.P. Testirovanie funkzii trombozitov dlya ozenki riska trombozov i krovotecheniy u bol’nych IBS, poluchayuschich antiagreganty [Platelet function test for the assessment of thrombosis and bleeding risk in CHD patients taking antiplatelet medications]. Rossiyskiy kardiologicheskiy zhurnal, 2015, vol. 20, no. 3, pp. 25–34. (in Russian).
14. Suleiman M., Khatib R., Agmon Y. Mahamid R., Boulos M., Kapeliovich M., Levy Y., Beyar R., Markiewicz W., Hammerman H., Aronson D.. Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein. J Am Coll Cardiol, 2006, vol. 47, no. 5, рр. 962–968.
15. Kohli P., Bonaca M.P., Kakkar R., Kudinova A.Y., Scirica B.M., Sabatine M.S., Murphy S.A., Braunwald E., Lee R.T., Morrow D.A. Role of ST2 in Non-ST-Elevation Acute Coronary Syndrome in the MERLIN-TIMI 36 Trial. Clinical Chemistry, 2012, vol. 58, no. 1, рр. 1–10.
16. Levin E.R., Gardner D.G., Samson W.K. Natriuretic peptides. N Engl J Med, 1998, vol. 339, no. 5, рр. 321–328.
17. Maisel A.S. Cardiac Biomarkers: Expert Advice for Clinicians, New Delphi : JayPee Brothers, 2012, 259 p.
18. Solomachina N.I., Belenkov Yu.N. Prognosticheskoe znachenie tkanevogo ingibitora matriksnych metalloproteinaz” 1 (TIMP”1) u bol’nych ChSN [Prognostic impact of tissue inhibitor of matrix metalloproteinase-I (TIMP-I) in patients with CHF]. Zhurnal Serdechnaya nedostatochnost’, 2010, vol. 11, no. 5(61), pp. 281–284. (in Russian).
19. Cavusoglu E., Ruwende C., Chopra V., Yanamadala S., Eng C., Clark L.T., Pinsky D.J., Marmur J.D. Tissue inhibitor of metalloproteinase-1 (TIMP-1) is an independent predictor of all cause mortality, cardiac and myocardial infarction. Am. Heart J, 2006, vol. 151, no. 5, рр. 1101–1108.
20. Lubos E., Schnabel R., Rupprecht H.J., Bickel C., Messow C.M., Prigge S., Cambien F., Tiret L., Münzel T., Blankenberg S. Prognos tic value of tissue inhibitor of metalloproteinase-1 for cardiovascular death among patients with cardiovascular disease: results from the atherogene study. Eur Heart J, 2006, vol. 27, no. 2, рр. 150–156.
21. Teplyakov A.T., Andriyanova A.V., Pushnikova E.Yu., Suslova T.E., Nikonova E.S., Konakov S.N., Rodionova O.A., Kuznezova A.V., Protopopova N.V. Tkanevoy ingibitor matriksnych metalloproteinaz-1 (TIMP-1) kak nezavisimyy marker ishemicheskogo remodelirovaniya miokarda pri chronicheskoy serdechnoy nedostatochnosti [Tissue inhibitor of metalloproteinase-1 (TIMP-1) as an independent marker of ischemic myocardial remodeling in heart failure]. Sibirskiy medizinskiy zhurnal (Tomsk), 2014, vol. 29, no. 2, pp. 28–34. (in Russian).
22. Teplyakov A.T. Chronicheskaya serdechnaya nedostatochnost’. Zitokinovaya ekspressiya, immunnaya aktivaziya i zaschita organov-misheney [Chronic heart failure. Cytokine expression, immune activation and target organ protection], Tomsk : Izd-vo Tomskogo un-ta, 2012, 294 s. (in Russian).
23. Tsapaeva N. L, Chtchupak О.V, Shpilevoj В.N. Laser based optoelectronic system for therapy by medical treatment of cardiovascular dieses. J Europ Biomedical optics, 1995, vol. 6, Sp. Issure, pp. 50–53.
24. Tsapaeva N.L., Anchikova E.R., Konstantinova E.E., Tolstaja T.N., Mironova E.V. New method of myocardial protection in -pass surgery with preoperative infrared laser treatment. J Inv Card, 2004,vol. 9, pp. 45–47.
25. Chaitman B., Pepine C., Parker J., Skopal J., Chumakova G., Kuch J., Wang W., Skettino S.L., Wolff A.A. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: A randomized controlled trial. JAMA, 2004, vol. 291, no. 3, рр. 309–316.
File extension: pdf (618.38 KB)